WO2014025199A3 - 스테필로코칼 엔테로톡신 유래의 초항원 변이체 및 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도 - Google Patents
스테필로코칼 엔테로톡신 유래의 초항원 변이체 및 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도 Download PDFInfo
- Publication number
- WO2014025199A3 WO2014025199A3 PCT/KR2013/007112 KR2013007112W WO2014025199A3 WO 2014025199 A3 WO2014025199 A3 WO 2014025199A3 KR 2013007112 W KR2013007112 W KR 2013007112W WO 2014025199 A3 WO2014025199 A3 WO 2014025199A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seb
- mutant
- target
- modified
- fusion protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
본원은 변형된 SEB(staphylococcal Enterotoxin B), 이를 코딩하는 폴리뉴클레오타이드, 이를 포함하는 벡터 및 숙주세포가 개시된다. 본원은 또한 본원에 따른 변형된 SEB 또는 야생형 SEB 및 이와 융합된 표적 특이적 폴리펩타이드의 융합단백질 및 이의 질환 치료제로서의 용도가 개시된다. 본원에 개시된 SEB 변이체 및 이를 포함하는 융합단백질은 특정 세포를 특이적으로 인식할 수 있도록 제조되어 면역계 활성화를 통해 암과 같은 특정 세포의 사멸을 유도하여 질환의 치료에 유용하게 이용될 수 있다.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2012-0087478 | 2012-08-09 | ||
KR20120087478 | 2012-08-09 | ||
KR1020130089540A KR20140021485A (ko) | 2012-08-09 | 2013-07-29 | 스테필로코칼 엔테로톡신 유래의 초항원 변이체 및 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도 |
KR10-2013-0089540 | 2013-07-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014025199A2 WO2014025199A2 (ko) | 2014-02-13 |
WO2014025199A3 true WO2014025199A3 (ko) | 2014-04-03 |
Family
ID=50068657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2013/007112 WO2014025199A2 (ko) | 2012-08-09 | 2013-08-07 | 스테필로코칼 엔테로톡신 유래의 초항원 변이체 및 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014025199A2 (ko) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
CN104974261B (zh) * | 2014-04-01 | 2019-06-14 | 三生国健药业(上海)股份有限公司 | 重组抗her2/ps双特异性抗体、其制备方法和应用 |
US11938193B2 (en) * | 2016-01-08 | 2024-03-26 | Washington University | Compositions comprising chemerin and methods of use thereof |
CN107236046B (zh) * | 2017-05-15 | 2021-05-07 | 江苏吴中医药集团有限公司苏州中凯生物制药厂 | 一种重组人内皮抑素融合蛋白及其制备方法和应用 |
US20210054042A1 (en) * | 2018-02-02 | 2021-02-25 | Univerza V Ljubljani | Affinity ligands for antibody fc region |
CN114848794A (zh) * | 2022-05-25 | 2022-08-05 | 沈阳协合生物制药股份有限公司 | 一种通过调节t细胞免疫预防和治疗骨质疏松病的方法 |
CN116284448B (zh) * | 2023-02-14 | 2024-06-21 | 浙江大学 | 一种超抗原参与的三功能t细胞衔接器及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5858363A (en) * | 1990-07-20 | 1999-01-12 | Pharmacia & Upjohn Ab | Target specific antibody-superantigen conjugates and their preparation |
US20050260215A1 (en) * | 1994-07-11 | 2005-11-24 | Lars Abrahmsen | Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate |
US20060024322A1 (en) * | 1998-02-15 | 2006-02-02 | Juridical Foundation The Chemo-Sero-Therapeutic Research And Kowa Company, Ltd. | Novel prophylactics/remedies for immunopathy |
US20060052295A1 (en) * | 2002-05-08 | 2006-03-09 | Terman David S | Intrathecal and intratumoral superantigens to treat malignant disease |
US8226958B2 (en) * | 2003-03-28 | 2012-07-24 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Modified SEB and prophylactics/remedies for immunopathy containing the same |
-
2013
- 2013-08-07 WO PCT/KR2013/007112 patent/WO2014025199A2/ko active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5858363A (en) * | 1990-07-20 | 1999-01-12 | Pharmacia & Upjohn Ab | Target specific antibody-superantigen conjugates and their preparation |
US20050260215A1 (en) * | 1994-07-11 | 2005-11-24 | Lars Abrahmsen | Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate |
US20060024322A1 (en) * | 1998-02-15 | 2006-02-02 | Juridical Foundation The Chemo-Sero-Therapeutic Research And Kowa Company, Ltd. | Novel prophylactics/remedies for immunopathy |
US20060052295A1 (en) * | 2002-05-08 | 2006-03-09 | Terman David S | Intrathecal and intratumoral superantigens to treat malignant disease |
US8226958B2 (en) * | 2003-03-28 | 2012-07-24 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Modified SEB and prophylactics/remedies for immunopathy containing the same |
Also Published As
Publication number | Publication date |
---|---|
WO2014025199A2 (ko) | 2014-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014025199A3 (ko) | 스테필로코칼 엔테로톡신 유래의 초항원 변이체 및 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도 | |
WO2014025198A3 (ko) | Lfa3 변이체 및 상기 변이체 또는 lfa3 cd2 결합영역과 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도 | |
PH12015500284A1 (en) | Interleukin-10 fusion proteins and uses thereof | |
TWI799368B (zh) | 抗tl1a抗原結合蛋白及相關核酸、表現載體、宿主細胞、醫藥組合物、方法及用途 | |
PH12017500939A1 (en) | T cell activating bispecific antigen binding molecules agiant folr1 and cd1 | |
PH12014502767A1 (en) | Interleukin-2 fusion proteins and uses thereof | |
WO2014200910A3 (en) | Bioinformatic processes for determination of peptide binding | |
WO2014145016A3 (en) | Il-22 polypeptides and il-22 fc fusion proteins and methods of use | |
MX2019006411A (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos. | |
WO2013184939A3 (en) | Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide | |
NZ719654A (en) | Interleukin-2 fusion proteins and uses thereof | |
MX2019007753A (es) | Polipeptidos que contienen fc con glicosilacion alterada y funcion efectora reducida. | |
WO2014011901A3 (en) | Methods and compositions for delivery of biologics | |
MX2019009191A (es) | Proteinas de fusion de enzima lisosomal terapeutica objetivo y uso de las mismas. | |
MX348071B (es) | Variantes de fc. | |
EA201491494A1 (ru) | Нацеливание на гликаны хондроитинсульфаты | |
TN2012000167A1 (en) | Human il-23 antigen binding proteins | |
WO2014005683A8 (en) | Dna vaccine for use in pancreatic cancer patients | |
MX2017014397A (es) | Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn). | |
PH12016500275A1 (en) | Antibodies | |
MD20140104A2 (ro) | Polipeptide care se leagă de CX3CR1 | |
WO2016077789A8 (en) | Neutralizing antibodies to ebola virus glycoprotein and their use | |
WO2013177593A3 (en) | Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies | |
MX356162B (es) | Sistema de expresion y secrecion. | |
EP3180463A4 (en) | Detecting residual host cell proteins in recombinant protein preparations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13828513 Country of ref document: EP Kind code of ref document: A2 |